title: [Treatment for overactive bladder].
abstract: BACKGROUND
  Epidemiological data demonstrate an increasing prevalence of symptoms of overactive bladder (OAB) with age not only in women, but especially in men. Despite a comparable prevalence, however, men are still highly underrepresented in most large randomized studies on the effect of antimuscarinic drugs.
  
  
  OBJECTIVE
  In this subgroup analysis of the CAP Study the efficacy and tolerability of solifenacin was examined in 111 men with symptoms of OAB. The study was performed in a network between general practitioners and urologists under routine conditions over a period of 12 months.
  
  
  RESULTS
  Treatment with solifenacin reduced all symptoms of OAB significantly, and the use of pads decreased by more than half. The tolerability of therapy was judged as "excellent" or "good" by over 95% of doctors and patients.
  
  
  CONCLUSIONS
  This subgroup analysis of the CAP Study confirms the good efficacy and tolerability of solifenacin in male OAB in daily practice over a treatment period of 1 year.
authors: Gesellschaft für Klinische Studien, Vituro GmbH, Käthe-Kollwitz-Straße 9, 04109, Leipzig, Deutschland. info@vituro.de
authors: P
authors: P
authors: Rothe
authors: M
authors: M
authors: Kalchthaler
authors: S
authors: S
authors: Mühlich
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D003299:Cooperative Behavior; D003430:Cross-Sectional Studies; D058006:General Practice; D006801:Humans; D033183:Interdisciplinary Communication; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D017060:Patient Satisfaction; D011812:Quinuclidines / Q000627:therapeutic use*; D012737:Sex Factors; D000069464:Solifenacin Succinate; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D053201:Urinary Bladder, Overactive / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D014563:Urodynamics / Q000187:drug effects; D055815:Young Adult
chemical_list: D018727:Muscarinic Antagonists; D011812:Quinuclidines; D044005:Tetrahydroisoquinolines; D000069464:Solifenacin Succinate